Paint and coatings producer/retailer with a network of 4,500 stores in the US, Canada & LatAm. 50% market share in the US, with the next 3 competitors at 15%, 15%, and 5%. An extremely profitable and well-managed franchise. Currently underearning due to temporarily depressed gross margins, expected to normalize by 2024 from 41% to 47%. Vertically integrated and controls local monopolies. The stock has declined +30% over the last few months in expectation of the housing slowdown.

Merger arbitrage with a 90% spread and trading below pre-announcement levels. SIMO is a decent buy at the current price regardless if the merger closes or not. To be acquired by $MXL at $93.54 in cash + 0.388x in MXL shares. Expected to close in H1'23. Buyer is also the main competitor, but product overlap is minimal and HSR has already been cleared. Chinese regulatory approval is the main risk as SIMO is a Taiwanese company. The recent request by the Chinese regulator to refile the merger application kind of puts the merger in limbo. The company and the buyer operating in the flash memory storage controllers industry.

Prem Watsa company trading at 0.56x BV. A bet on it mean reverting closer to 0.8x - 0.9x BV as it has done a number of times in the past. Trades at discount to BV due to a drop in the Indian Rupee, emerging markets being out of favor, and investors being scared of the impact of high energy prices on emerging markets. BV per share has doubled over the last 7 years. History of large buybacks and ongoing open market purchases. Current BV calculations appear to be based on conservative assumptions.

Subprime and near-prime online lenders to consumers and SMBs. The stock is very cheap (PE of 4x-6x), and the business is substantially overcapitalized/underlevered. ENVA is exceptionally well run with thoughtful/prudent/disciplined underwriting. Having achieved the necessary scale, the cmpany is well-positioned with a very long runway for earnings growth. Management is aggressively repurchasing shares at highly accretive prices ($217m LTM buybacks out of $1.2bn mcap). The market is overestimating the risk of material consumer credit losses.

Two businesses under one roof: rental of trucks and related moving equipment and owner/operator of self-storage. The stock is cheaper (8x-10x EPS) and the business is stronger and more overcapitalized than ever. The market overestimates UHAL’s COVID benefit - two factors drove structurally sustainable earnings growth: (1) lease-up of self-storage properties that were with zero occupancy initially and (2) truck and equipment rental price increases. UHAL’s brand equity and related competitive moat are underappreciated - the company is dominant in organic web search traffic. Management talks openly about taking actions to close the long persisting valuation gap.

Life sciences company that pioneered the single-cell category within genomics. TXG operates with a razor-and-blade model with 85%+ of its sales being high-margin consumables. Trades at its lowest valuation since its IPO in 2019 due to the impact of a transitioning customer base in the US, a supply chain stumble in Europe and the complete shutdown of genomics labs in China. However, fears are overblown. Growth is set to reaccelerate next year with plenty of headroom for further expansion as TXG single-cell technology continues to gain popularity among academic labs as well as pharma. Management expects to reach profitability in 2023. TXG has the potential to achieve 30%+ operating margins in line with $ILMN, which has a similar razor-and-blade business model.

High-quality enterprise SaaS business with 85% of recurring revenue, 110%+ net revenue retention, and multi-year contracts. Provides mass notification and critical event management software - given the increasingly risky operating environment enterprise clients are unlikely to cancel subscriptions in a recession or downturn. EVBG is too cheap, trading at 4x 2023 revenue multiple and a reasonable multiple of forward EBITDA. Activist investor Ancora Advisors took a stake in Everbridge and has been publicly pushing the board to sell the company. According to Ancorra, there are likely several interested private equity buyers. The new CEO is no stranger to selling public companies. 3 directors have made pen market purchases at much higher prices.

Robinhood is one of the best consumer products of all time, and the market is currently valuing its ongoing operations at just over $2bn, well below takeout value. A turnaround play in its current form. To turn profitable HOOD must (1) radically reduce expenses, (2) aggressively pursue larger accounts from the likes of $SCHW, $TD, $IBKR, and Etrade, (3) repair the brand so it is seen as a bona fide financial institution consumers trust. If they can execute well on those 3 objectives, HOOD is double from current levels. Potential takeout target - FTX has already been reported as being potentially interested and its CEO @SBF_FTX personally bought ~7.6% of the company.

Dominant media company in NZ, owning half the print market; 40% of the radio market; & a quarter of the digital display market. Trades at 6x FCF. History of material buybacks/dividends. Expected to return half the mcap to shareholders over the next 3 years. Capital allocation risks have been reduced over the past 18 months.

Aluminum producer with exposure to the packaging, aerospace, defense, auto, and general industrial sectors. Macro headlines and European energy availability/concerns have weighed on the stock but the damage is too severe. The management team is executing well and focused on FCF. Company earnings are set to benefit from the recovery of aerospace earnings lost during covid, recently restructured beverage contracts as well as continued cost-saving initiatives. CSTM has materially reduced leverage and now has a favorable maturity ladder with ample liquidity. Cheap valuation across several metrics - the stock is at least double from current levels.

Special situation biotech that is a 'process' and not a 'science' play. 90% chance of being up 100% and a 10% chance of being down 50% over the coming weeks/months. Phase I, Phase II, and Phase III have already been completed with great data. But MIST screwed up the presentation of the Phase III data resulting in denied FDA approval. Just finished re-running the trial and is due to re-present the data in the back half of the year.

P&C insurer that has been under-earning in their U.S. personal auto business since mid-2021. Sold-off after Q2 earnings due to inflationary headwinds, however, the auto margins are likely to be at or near trough levels. Margins are set to expand given implemented rate adjustments to counter inflation, favorable macro indicators as well as reserves already being in line with best-in-class peers. Normalized auto margins and profitability levels are expected by early 2024. ALL expected to re-rate as investors see a cleaner roadmap back to normalized earnings power.

Arbitrage play between $APE & $AMC stock - both economically equivalent. 23% spread. However, borrowing for AMC is tight and there is a short-squeeze risk. New APE-preferred securities were created for AMC to have issuance currency without requiring shareholder approval.

Leading North American manufacturer of towable RVs, motorhomes, and boats. Investors are wrong in thinking that the recent revenue and earnings growth is almost entirely due to it being a Covid winner. Actually, growth was mainly driven by: 1) secular growth in the RV industry and market share gains, 2) smart acquisitions, and 3) cost-cutting initiatives and efficiency gains. The business has been transformed over the last 5 years. Low investor sentiment - short interest at 18%. Normalized EBITDA has more than doubled from 2019 driven by the factors listed above.

LendingClub - structurally transformed business after the acquisition of Radius Bank in Feb'21. Cheap at 6.5x 2023 earnings and 1.3x TBV. The bank enables LendingClubC to retain higher-yielding loans and fund them with stable, low-cost deposits as well as reduces reliance on third-party funding. Previously LC generated revenues from transaction fees only. With the bank's CET1 ratio of almost 19% (higher than almost any other bank) the company could potentially initiate a share buyback plan in the next 6 to 9 months. ROTCE in low to mid 20's. LendingClub is primarily used to consolidate or refinance credit card debt and save money through lower interest rates and fees. Significant run-way to take market share in the $1 Tr credit card market.

Pentamaster International - provider of automated testing equipment and factory automation solutions. Trades at only 9x earnings. Fast-growing business at a heavily discounted price, with high returns on capital, significant tailwinds, diversified revenue streams and run by conservative management who has built up a significant net cash balance across the years. The company is 64% owned by Malaysia's listed parent, which is a stock market darling and trades at 39x PE. Wide valuation discrepancy despite Pentamaster International contributing more than 100% of the parent's earnings.

Solid bank franchise with good earnings power that has the potential to be swept up in the wave of community bank M&A over the next several years. Trades at an undemanding 1.2-1.3x TBV with 12%-13% ROE and a history of solid loan underwriting. The bank is one of the final remaining independent community banks in the $1-$2 billion asset range in a rapidly consolidating northern Ohio market. Currently, MBCN is acquiring $LBSI - this acquisition will greatly change the profile and governance of the bank. Will have Castle Creek among its shareholders and board - investor with a phenomenal track record in community banks with virtually all portfolio companies getting sold eventually.

Currency exchange service provider - both physical and digital. Trades at only 9.5x fwd earnings. Significant upside potential from both business segments and strong downside protection with net cash equivalent to the current mcap. The payments segment transformed from minuscule to $9.6m TTM revenue over the last couple of years driven by continued growth in transacting bank count. The banknotes segment (FX retail kiosks) is set to continue recovering with travel returning to pre-pandemic levels (still only at 70%-90% levels). The retail business also benefits from Travelex closing its North American operations during the pandemic. Wholesaling dollar notes internationally will add a third major revenue driver for the company. Financial performance has materially improved over the last few quarters and profitability for the whole company has already reached/exceeded pre-pandemic levels.

Licensor of table games to traditional casinos - unique IP assets. Strong unit economics with 98%+ gross margins and 50% EBITDA margins. Projected to double EBITDA from '22 to '25. 200%+ upside. Potential to become a multi-year compounder. Multiple growth drivers - licenses in new states, signing up more casinos, upselling existing casinos, and iGaming. The litigation overhang is gone. An activist private investor was recently appointed to the board.

Electronics components manufacturer in the early innings of credible and so far successful turnaround led by new CEO. Trades at 5x-6x EBITDA, well below peers. Significant strides have already been made and results of the last few quarters have derisked the story. Plenty of low-hanging fruit left that will allow company to double its EBITDA margins to 15% and in turn drive re-rating closer to peer multiples. Due to a lack of oversight some-pockets of the business was operating at negative gross margins. Aside from the company-specific story - long-term secular tailwinds in "electrification of everything".

Unique bank with phenomenal returns on capital run by great management trading at 7.6x earnings. Leader in Italian factoring and specializes in the non-recourse sale of trade receivables from the National Healthcare System and the public administration. Also has similar operations in Spain and Portugal. Unique niche with very limited credit risk. 35% returns on tangible equity. Shareholder-friendly management, which understands capital allocation and pays out 100% of earnings in dividends. 11.7% dividend yield.

Consolidator of IT service providers with 30+ acquisitions since 2017. Successful roll-up that is able to extract cost & revenue synergies from its acquisitions as well as generate high-single-digit organic growth. Currently sits at 11x EBITDA, which does not incorporate recently completed acquisitions. Expected to continue growing through M&A and could double in size over the next 3-4 years. Further M&A will be financed by internally generated FCF and equity raises are being replaced by the recently announced share buyback.

Harley-Davidson - iconic brand with 70+% market share in the core heavyweight bike market. Trades at 8x EPS/FCF as it is perceived as a melting ice cube due to secular demographic headwinds. However, the new CEO is reinvigorating growth and profitability by refocusing the business on core geographies and bikes. He previously succeded in bringing Puma from the brink of bankruptcy to a 4000% stock return. HOG needs to reach $70/share (75% upside) for the incentive package to kick in. Margins are already improving vs 2019 and approaching the heydays of pre-GFR Harley. Dealer $ and margin profitability in ’21 was a 25+ year high, despite inventories down 70+%. CEO personally purchased $5m of stock.

Natural-gas weighted mineral royalty MLP with well-protected downside and potential upside coming in for free. Currently generates 11.5% distribution yield despite production hedged at $66 oil and $3 gas., hedges for 2023 protect from fall in commodity prices. Upside from expected 15-20% production growth over the next 6 quarters. Potential for significant upside should the “higher-for-longer” thesis on natural gas prices come to pass. Significantly reduced debt over the last 3 years from $400m to <$100m.

Exemplary banking operations are run by conservative managers with a deep understanding of real estate lending and an intense focus on costs. At 10x PE priced in line with the average bank despite being a far superior business. The continued compounding of equity capital will result in a 4x - 6x return over 10 years. Expected to generate ROE of 15-20% over the next decade. Sits at 1.7x BV, near its 5-year low. The bank is family run with insiders owning 31% - a long track record dispels any concerns of nepotism. Mostly single-family and multifamily residential portfolios. Only loans personally assessed by the board are on the books with an intense focus on collateral - LTV by 53%. Net charge-offs are almost non-existent. Interest rate sensitivity (especially for over longer periods) is somewhat protected due to 66% of assets in adjustable rate loans. Reinvests most of the earnings to compound capital - only 10% dividend payout ratio.

UK used car retailer at 10x PE. Management recently initiated a new strategy to double market share by investing in e-commerce tech and marketing, which will result in depressed ST profits. Although investors were not excited about this (stock price halved from the peak), management is accelerating investments as the strategy is working and key competitors are fighting for survival. Profits are expected to more than double over the next 3 years with the company generating substantial cash and likely launching of buyback. CEO owns 10% of the company.

Pharmacy service provider priced as if it is heading for bankruptcy. 40% market share in its niche of medication risk management. Recurring, subscription-based revenue stream. Recent and pending non-core software assets sales will bring around $250-$300m and remove liquidity concerns, materially reduce leverage, and simply the equity story. The remaining business is set for double-digit annual growth over the next five years.

Global provider of specialty chemicals. with 75% sales in NA. #1 or #2 players in its end markets with minimal competition. At 6.5x EBITDA materially cheaper (50% discount) than peers, but with better growth, margins, and cash flow conversion. Recently announced revised capital allocation strategy with buyback plan for more than 1/3 of market cap over the next 4 years. PE overhang as CCMP is selling down its stake - reduced from 39% a year ago to 24% currently. Insiders purchased $1.2m shares at current prices.

Post-merger S&P Global and IHS Markit - high-quality compounder set to return a significant amount of cashflow to shareholders once IHS Markit integration is complete and synergies are realized. Collection of very high-quality businesses with strong historical revenue growth, pricing power, high margins, low capital intensity, and customer stickiness. Expected double-digit growth in FCF per share coming from debt boost of incremental borrowings and repurchases of significant amounts of stock.

A bet on a recovery in the global travel industry to 2019 levels. The second largest GDS with 35% market share. GDS - booking software, essentially operates as a middle man between travel agents and hotels and airline reservation systems. The business was decimated by COVID travel restrictions and stock is down 66% since 2019. Now we are at the turning point with enough outlook as things continue to open up. Management stays strong in its long-term outlook and walks down the path to recovery with confidence. Oligopolistic industry structure with 3 players commanding 80% share. The company is extremely entrenched in the US travel market.

Trades 30% below IPO, despite being on pace to 2.5x revenue vs 2019 and generating substantially improved profitability. Contrary to market skepticism, Uber's ridesharing business is already highly profitable (+25% EBITDA margins), and generates incremental margins north of 50%. Delivery business, which hardly existed at the time of IPO, today accounts for 60% of bookings and has grown +90% annually since 2018. Consolidated margins are set to continue expanding and gradually approaching an incremental 35%. Multi-product capability is an underappreciated structural competitive advantage versus its single-product competitors. Set up to meaningfully exceed investor profit expectations post-issuance of highly conservative 2024 EBITDA guidance of $5bn.

A global leader in the distribution of fresh fruits and vegetables - busted IPO from 2021. 1.7x the size of its biggest competitor. Trades materially below peers and historical valuations. Temporary issues and product recalls have impacted profitability and caused a share price slump post IPO. Once resolved, the valuation gap to peers should close. Management is owner-operators - well-respected industry veterans with a long track record of managing the business for the long term. Insiders own 10% of the company.

Pre-deal SPAC warrants, sponsored by the most ruthless vulture hedge fund Alden Global. The market underestimates the chances of the deal getting done and prices in mostly liquidation. 10x upside on warrants upon de-SPAC. Might be one of the rare SPACs with actual positive ROI. Alden has a great track record in buying newspapers, cutting costs to the bone, and milking them for cash. 40 years of anecdotal evidence of them making a lot of money on distressed purchases. Led by Randy Smith - one of the best and most successful distressed investors of all time. Alden/Randy is allergic to losing money - and therefore unlikely to simply liquidate the trust after investing $6m. Has till Jan'23 to consummate the transaction. De-minimis closing risks as Alden can source its own funding and is not reliant on PIPE markets.

Global commercial real estate services firm, one of three players with breadth and scale to win contracts with large, multinational clients. Trades at 7x PE after a recent 30% decline in share price. Investors fear that CWK is set for material decline due to a slowdown in the economy. However, the business is more resilient to a potential downturn than the market appreciates. 75% of earnings are from recurring and predictable services and fees, leaving only 25% of profits exposed to the economic cycle. And even for this more cyclical part, the slowdown is expected to be milder due to the dynamics of commercial real estate markets. In a longer-term - attractive industry with favorable competitive dynamics and long-term growth tailwinds.

A front door to US residential real estate with 2/3 of home buyers use Zillow. Currently under-monetizes its powerful position. A recently introduced Flex pricing model will drive improved monetization by aligning Zillow's and agents' incentives better. Inroads into new products such as mortgage origination or closing services are expected to have a material impact down the road. Wind-down of the iBuying will free up capital on the balance sheet, leaving the company with meaningful net cash.

Restaurant franchisor in US and Canada at 11x FCF. 80 banners and 6.7k units. High-quality business with sustainable double-digit growth potential. It relies on the combination of attractively priced acquisitions and effective cost-cutting to grow at attractive rates of return. Investors misperceive the company as a melting ice cube with weak and unprofitable franchisees. However, management is gearing towards generating value through acquisitions of less-sexy (and in turn cheaper) mature brands and not necessarily growing the existing operations. Organic growth is zero/negative almost by the design of the strategy. Tons of dry powder to deploy in a proven and underappreciate acquisition strategy with high returns.

Producer of Embraer jets and other aircraft - undervalued on every valuation metric and historical multiples. The core business is set to recover to mid-cycle levels over the next 1-2 years. A strong backlog - the highest level since 2015 - suggests several years of significant growth. Owns 90% of $EVEX - a recent spin-off developing electric vertical takeoff and landing vehicle with deliveries expected in 2026. The current ERJ market cap is 20% below the value of retained EVE ownership.

Highly levered oilfield service company. Extreem optionality on rapidly improving US onshore oil services activity and pricing. Stock could be 7x by 2023. Gradually growing revenues and EBITDA are expected to lead to organic deleveraging and positive FCF by 2023. Limited capex needs going forward, with half of EBITDA expected to transalte into FCF. Revenue is highly correlated to industry activity. The E&P industry underinvested since 2014 and now needs to catch up with the demand.

Operator and serial acquirer of web-properties trading under 9x EBITDA and runway for further consolidation and growth in the mid-term. Parent of the recent $CCSI spin-off - investors still anchor valuation to the spun-out legacy fax assets. Current assets include Pcmag.com, Mashable, and BabyCenter). Earns revenues from advertising and subscriptions. Over the last 5 years grew revenues and EBITDA at a 20% CAGR. Platform to grow via a proven M&A strategy - 500 opportunities evaluated during 2021 alone. Management aims to double the size of the business every 5 to 6 years.

Pharma company in phase 2 clinical trials for an innovative cannabis intoxication treatment - no alternatives for it currently and presents a huge market opportunity worth hundreds of millions or even billions. ANEB's drug has already been validated by several studies and excellent Phase II topline results. Hopes to file IND with FDA by the year-end. Large and growing target market with increasing legalization/consumption of cannabis. 90% are owned by insiders. The existing cash balance of $16m is likely to prove inadequate to reach FDA approval, i.e. expected dilution.

A high-quality business with high margins, strong cash flow, and potential for future margin expansion as the business grows. Unlike other covid beneficiaries, ETSY is likely to keep the gains it experienced during the pandemic. Strong network effects. Set to benefit from continued commerce shift online. Currently trades at only 20x FCF. With mid-single-digit growth, a slight increase in the take rate, and some incremental margin leverage the stock is expected to compound at double-digit rates moving forward.

O&G company with cash-flowing energy assets in Canada, offshore Malaysia, and France. Cheap on the valuation of its reserves and relative to peers. Flush in cash today - set to generate 28% of its market cap in 2022 FCF. Stands out from its peers in terms of capital allocation with management extremely capable of increasing company per-share value during the lean times.

Potential liquidation: busted oil exploration junior now in quasi-runoff mode, offering at least a ~35% gross return and potentially a ~69% IRR over a likely 12-month period. The wind-up has not been formally announced, but all signs are there. Cash covers 58% of the market cap and the remaining upside/value comes from earnout on the previous asset sale. The earnout is very likely to pay out fully by mid-2025 or management will find a way to monetize it earlier.

Medical device company with a QuantaFlo product for detecting Peripheral Artery Disease (PDA). The product is easier to use and lower cost compared to other PDA testing methodologies. Studies have shown that QuantaFlo is at least as good as other testing alternatives. The upside is based on continued gradual penetration increase and revenue growth. PDA is a chronic disease that so far goes undetected in c. 30% of a given doctor's older population. Bearish concerns of QuantaFlo being to-good-to-be-true or regarding lack of clarity if insurers will compensate testing are overly exaggerated.

Online brokerage for retail customers and provider of services for RIAs. Set to benefit from: (1) asset gathering tailwinds for electronic brokerage firms, attracting net new client assets of $20-60bn each month; (2) Inflation and higher interest rates as it sweeps clients' excess cash into its bank; (3) massive synergies from its TD Ameritrade acquisition, management estimates these at $4.3-4.8bn.The company is accelerating capital returns with increased dividends and $15bn buyback authorization. CEO / co-Chairman recently made a $9.5m open market purchase.

A top pick for a bet on Uranium price spike for $150/lb by 2026. The company has 90m lbs of M&I resources across 4 locations in the US, coming online in 2023-2027. Fully funded to start production in Texas by Q323, reducing the risk of dilution. Great management track record - Chairman has grown his previous mining company 1000x before selling it to Uranium One, albeit that was 15 years ago.

Offshore support vessel operator with 174 vessels globally. Well-positioned play for a recovery in offshore activities - cleanest balance sheet of major competitors and one of the most modern fleets. Enormous operating leverage if industry economics return to 2014 levels. Tight vessel supply amidst growing demand and premium vessel fleet expected to shrink over the next few years given limited incoming new builds and age/emission restrictions from the clients.

LG Corp - holding company at 67% discount to SoTP of listed subs. Something like 29 trading for 12.5. The listed subs are cheap at single-digit PEs. The key asset is LG Chem, which owns LG Energy Solutions - the second largest auto electric battery manufacturer - a highly prized global business. But this is in Korea where the sum of the parts valuations go to die. Still, there is a chance this will reverse to something like a 25% discount typical for Europe.